Prachi Desai

1) Led and contributed to pre-clinical development of radiopharmaceuticals for oncology programs, including 225Ac-SSO110, which progressed to first-in-human dosing 2) Led and coordinated pre-clinical studies including in-vitro assays, biodistribution, efficacy, dosimetry, IHC across programs involving alpha, beta, and Auger emitters 3) Established, optimized, and conducted in-vitro studies for alpha, beta, and Auger-emitting radiopharmaceuticals 4) Collaborated with external partners to support mRNA display, contributing to early-stage discovery projects 5) Presented project findings to cross-functional internal teams and at international scientific conferences

Jul 2022 - Dec 2022 (On site) 1) Optimized nanogel formulations for in-vivo therapeutic applications 2) Evaluated receptor expression profiles in response to varying treatment doses 3) Conducted in-vitro analysis of activated macrophage surface markers under different conditions Dec 2022 - Jun 2023 (Remote) 1) Conceptualizing, writing, editing, and proof-reading manuscript for clusters of excellence ‘‘TransMedMat’’ project

Potential of theranostic nanogels for endogenous radiotherapy 1) Formulation development, in-vitro, in-vivo evaluation of radiolabeled nanogels and peptides 2) Radiolabeled peptides and nanogels using gallium-68 and lutetium-177 3) Demonstrated strategies that improved cellular uptake, circulation time, tumor accumulation and efficacy of radiolabeled nanogels and peptides Additional experience: 1) Planned, executed, and analyzed multiple research projects from inception to completion 2) Assisted in drafting funding proposals, including DFG and animal study applications 3) Managed collaborative projects and maintained communication with partners to align goals and share results 4) Presented research findings through poster sessions and oral presentations at scientific meetings

1) Developed, and characterized complex injectable formulations, including microparticles and liposomes 2) Prepared study documentation and scientific reports summarizing data and outcomes 3) Collaborated effectively with cross-functional teams across multiple scientific and technical disciplines

1) Developed and characterized microsphere formulations for extended release of small molecules and proteins 2) Optimized formulations to meet targeted drug release profiles 3) Presented research findings through oral presentations to internal audiences

1) Synthesized and characterized modified Pluronic polymer

1) Formulation development, characterization and in-vitro evaluation of protein-loaded polymeric nanoparticles 2) Authored a book chapter on nanomaterials for dental tissue engineering, highlighting material applications and advantages in dentistry 3) Supervised undergraduate research projects

1) Formulation development, characterization, and in-vitro evaluation of magnetic liposomes for lung cancer therapy

Genomic DNA isolation, amplification, ligation and cloning

Potential of theranostic nanogels for endogenous radiotherapy

University of Groningen is one of the partner universities of the consortium CEMACUBE (Common European Masters Course in Biomedical Engineering). This gives opportunity to students to complete their master course in two different universities. At the end, master degree is obtained from both the universities. My choice of second year was University of Groningen.

Ghent University is one of the partner universities of the consortium CEMACUBE (Common European Masters Course in Biomedical Engineering). This gives opportunity to students to complete their master course in two different universities. At the end, master degree is obtained from both the universities. My choice of first year was Ghent University.